Jonathan joined Brandon Capital in 2021.
Jonathan is a Partner at Brandon’s London office and serves on the boards of Pheon, Myricx Pharma, NRG Therapeutics, AstronautX, Salvina, and Catalym. Previously, he was a Managing Director at Arix Bioscience, where he built the team and portfolio, sitting on boards including Artios Pharma and VelosBio (acquired by Merck for $2.75bn). Before Arix, Jonathan was a Principal at Touchstone Innovations, helping build biotech spin-outs like Inivata (acquired for $415m). He also worked at LifeArc in drug discovery.
Jonathan holds a first-class Biology degree from Oxford, a PhD in Molecular Medicine from UCL, and an MBA from Imperial College London. He conducted postdoctoral research on cancer cell signalling at Cancer Research UK, publishing in Nature Genetics and NEJM. He is a trustee of the Autism Centre for Excellence and advises KHAN drug discovery fund.
